Global Health Limited has informed the Exchange regarding Change in Director(s) of the company.
MEDANTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Global Health Limited (Medanta) reported strong Q1 FY26 results with standalone revenue from operations of Rs 8,821.56 million, up about 16% year-on-year, and standalone profit after tax of Rs 1,519.64 million, up roughly 40% from Rs 1,085.51 million in Q1 FY25 (restated). Consolidated revenue grew to Rs 10,308.37 million with profit after tax of Rs 1,589.82 million, nearly 50% higher year-on-year. The Board has recommended a final dividend of Rs 0.50 per equity share for FY25, with the record date set for August 22, 2025, subject to shareholder approval at the 21st AGM scheduled for September 19, 2025 via video conferencing. The Board also recommended re-appointment of founder and CMD Dr. Naresh Trehan for another 5-year term from August 1, 2026, and second 5-year terms for Independent Directors Vikram Singh Mehta and Hari Shanker Bhartia. M/s MAKS & Co has been proposed as the new Secretarial Auditor for 5 years from FY26. Under the ESOP scheme, 595,500 stock options were granted and 163,000 shares allotted to the employee welfare trust during the quarter.
Strong quarterly earnings growth and a modest dividend should be viewed positively by shareholders, though the stock is unlikely to see a major reaction given the results were largely a continuation of the post-merger growth trend. Re-appointment of the founder-promoter CMD and experienced independent directors signals continuity in strategy and governance.